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Recent evidence showed the role of peroxisome proliferator-activated receptors (PPARs) in cardiac function. Cardiac contraction
induced by various agents is critical in restoring the activity of peroxisome proliferator-activated receptors δ (PPARδ) in cardiac
myopathy. Because dobutamine is an agent widely used to treat heart failure in emergency setting, this study is aimed to investigate
the change of PPARδ in response to dobutamine. Neonatal rat cardiomyocytes were used to examine the eﬀects of dobutamine
on PPARδ expression levels and cardiac troponin I (cTnI) phosphorylation via Western blotting analysis. We show that treatment
with dobutamine increased PPARδ expression and cTnI phosphorylation in a time- and dose-dependent manner in neonatal rat
cardiomyocytes. These increases were blocked by the antagonist of β1-adrenoceptors. Also, the action of dobutamine was related
to the increase of calcium ions and diminished by chelating intracellular calcium. Additionally, dobutamine-induced action was
reduced by the inhibition of downstream messengers involved in this calcium-related pathway. Moreover, deletion of PPARδ using
siRNA generated the reduction of cTnI phosphorylation in cardiomyocytes treated with dobutamine. Thus, we concluded that
PPARδ is increased by dobutamine in cardiac cells.
1.Introduction
Dobutamine is one of the most widely used agents for
heart failure in clinic settings [1]. Dobutamine acts through
the activation of β1-adrenoceptor which is linked to a
guanine nucleotide regulatory cascade via heterotrimeric G
proteins. This activation results in an increase of adenylyl
cyclase activity for the conversion of adenosine triphosphate
(ATP) to cyclic AMP (cAMP). An increase in intracellular
cAMP concentration causes the release of calcium from
sarcoplasmic reticulum. This increased calcium is used by
contractile proteins to increase stroke volume [2–6].
Troponin I (TnI) is an inhibitory unit of the troponin
complexassociatedwiththinﬁlamentsandactsbyinhibiting
actomyosin interactions in the presence of low levels of
intracellular calcium ions (Ca2+) during diastole [7, 8].
Modulation of myoﬁlament properties via changes in TnI
phosphorylation has profound eﬀects on cardiac contrac-
tility and pumping [9]. Phosphorylation of TnI by protein
kinase A results in a reduction in myoﬁlament sensitivity
to Ca2+ and an increase in the cross-bridge cycling rate,
resulting in the acceleration of relaxation and an increase in
power output, but a reduced economy of contraction [8, 9].
Ca2+ is involved in muscle contraction and is an intracellular2 The Scientiﬁc World Journal
messenger that activates a wide variety of cellular responses
including gene transcription [7–10].
Various studies have shown that the activation of cal-
cineurin (Cn) and calcium/calmodulin-dependent protein
kinase (CaMK) signaling pathways serves a major role in the
regulation of gene expression in cardiac muscles [11, 12].
These same genes have been shown to also be regulated by
peroxisome proliferator-activated receptors (PPARs) [13].
PPARs are ligand-activated transcription factors that
regulateexpressionofgenesinvolvedinlipidmetabolismand
inﬂammation [13]. The three subtypes of PPARs (PPARα,
PPARγ,a n dP P A R δ) modulate expression of diﬀerent genes
and exert various bioactivities [13]. Previous studies also
showedthatmetabolic modulatorscanhavebeneﬁcialeﬀects
in both experimental and clinical heart failure settings
[14]. PPARδ-dependent maintenance of cardiac function
is crucial for cardiomyocytes [15–17]. The deletion of
cardiacPPARδ resultsindecreasedcontraction,increasedleft
ventricular end-diastolic pressure, lowered cardiac output,
andincreasedincidencesofcardiacfailure[15].Ourprevious
study demonstratedthatdigoxin enhancedcardiacoutputby
increasing PPARδ expression [18].
Dobutamine is the widely used cardiac agent for pa-
tients with heart failure. However, the theory is that the
action of dobutamine occurs via the activation of PPARδ
remained obscure. In this study, we used the neonatal
rat cardiomyocytes to investigate the role of PPARδ in
dobutamine-induced action. Moreover, we determined the
possible signaling pathways for increase of PPARδ induced
by dobutamine.
2. Methods
2.1. Materials. Dobutamine, atenolol, butoxamine, and
cyclosporine A were purchased from Sigma-Aldrich (St
Louis, MO, USA). BAPTA-AM and KN93 were purchased
from Calbiochem-Novabiochem Corp (La Jolla, CA, USA).
The ﬂuorescent probe, Fura2-AM, was obtained from
Molecular Probes (Eugene, OR, USA). The Opti-MEM
I Reduced Serum Medium, Stealth Select RNAi (siRNA-
PPARδ), scramble siRNA (siRNA-control), and Lipofec-
tamine 2000 were purchased from Invitrogen (Carlsbad, CA,
USA). Antibodies to PPARδ and actin were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibod-
ies to cardiac TnI and phospho-TnI (Ser 23/24) were pur-
chased from Cell Signaling Technology (Beverly, MA, USA).
2.2. Cell Culture. Primary cultures of neonatal rat cardiomy-
ocytes were prepared by the modiﬁcation of a previously
described method [14]. Brieﬂy, under anesthesia with 2%
isoﬂurane, hearts of 1-to-2-day-old Wistar rats were excised,
cut into 1-2mm pieces, and predigested with trypsin to
remove red blood cells. The heart tissue was then digested
with 0.25% trypsin and 0.05% collagenase. The dissoci-
ated cells were placed in uncoated 100mm dishes and
incubated at 37◦Ci na5 %C O 2 incubator for at least
1 hour to remove the nonmyocytic cells. This procedure
caused ﬁbroblasts to predominantly attach to the dishes
while most of the cardiomyocytes remained in suspension.
The cardiomyocyte-enriched population was collected and
counted. The cells were cultured in Dulbecco/Vogt modiﬁed
Eagle’s minimal essential medium (DMEM) with 1mmol/L
pyruvate, 10% fetal bovine serum (FBS), 100 units/mL
penicillin, and 100 units/mL streptomycin. Over 95% of
the collected cells were characterized cardiomyocytes on the
basis of the sarcomeric myosin content. On the second day,
the medium was replaced. After 3 to 4 days in culture, the
cells were exposed to hyperglycemic conditions. The high
glucose-treated cardiomyocytes were generated by applying
30mmol/L glucose to the cells for 24 hours [14]. This animal
experiment was approved and conducted in accordance
with local institutional guidelines for the care and use of
laboratory animals in the Chi-Mei Medical Center (number
100052307) and followed the Guide for the Care and Use of
LaboratoryAnimalspublishedbytheU.S.NationalInstitutes
of Health (NIH Publication number 85-23, revised 1996), as
well as the guidelines of the Animal Welfare Act.
2.3. Drug Treatment of Cardiomyocytes. Stock solutions of
dobutamine were prepared with normal media. Cells were
treated with varying concentrations of dobutamine (0.01–
10μmol/L)for4hours,washedtwicewithPBS,andremoved
by trypsinization. The treated cells were then collected
and subjected to a gene expression assay. In addition, pre-
treatment with various inhibitory agents (β1-adenocepotor
antagonist (10μmol/L atenolol) [19, 20], β2-adenocepotor
antagonist (10μmol/L butoxamine) [21], calcium chelator
(25mmol/L BAPTA-AM), calcineurin inhibitor (1μmol/L
cyclosporine A) [22], or CaMK inhibitor (1μmol/L KN-
93) [22]) was applied for 30 minutes before the addition of
dobutamine.
2.4. Western Blotting Analysis. Protein was extracted from
tissue homogenates and cell lysates using ice-cold radio-
immunoprecipitation assay (RIPA) buﬀer supplemented
with phosphatase and protease inhibitors (50mmol/L
sodium vanadate, 0.5mmol/L phenylmethylsulphonyl ﬂuo-
ride, 2mg/mL aprotinin, and 0.5mg/mL leupeptin). Protein
concentrations were determined with the Bio-Rad protein
assay (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Total
protein (30μg) was separated by SDS/polyacrylamide gel
electrophoresis (10% acrylamide gel) using the Bio-Rad
Mini-Protein II system. Protein was transferred to expanded
polyvinylidene diﬂuoride membranes (Pierce, Rockford, IL,
USA) with a Bio-Rad Trans-Blot system. After the transfer,
the membranes were washed with PBS and blocked for 1
hour at room temperature with 5% (w/v) nonfat dry milk
(NFDM) in PBS. Blots were incubated overnight at 4◦C
with an immunoglobulin-G polyclonal rabbit anti-mouse
antibody (Aﬃnity BioReagents, Inc., Golden, CO, USA)
diluted 1:500 in 5% (w/v) NFDM dissolved in PBS/Tween
20(0.5%byvolume).Theblotswerealsoincubatedwithgoat
polyclonal antibody (1:1000) targeted to actin, which served
as an internal control. After the removal of the primary
antibody, the blots were extensively washed with PBS/Tween
20. The blots were then incubated for 2hours at roomThe Scientiﬁc World Journal 3
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Figure 1: Eﬀects of dobutamine on PPARδ expression in neonatal rat cardiomyocytes. The neonatal rat cardiomyocytes were treated with
dobutamine at various concentrations for 4hours (a) or at 1μmol/L during various time points (b). The treated cells were harvested to
determine the protein levels by Western blotting analysis. All values are presented as mean ± SEM (n = 6 per group). ∗P<0.05 and
∗∗P<0.01 as compared with the vehicle-treated control group.
temperature with the appropriate peroxidase-conjugated
secondary antibody diluted in 5% (w/v) NFDM dissolved in
PBS/Tween20.Theblotsweredevelopedbyautoradiography
using the ECL-Western blotting system (Amersham Inter-
national, Buckinghamshire, UK). The immunoblots were
quantiﬁed with a laser densitometer.
2.5. Measurement of Intracellular Calcium Concentration.
The changes in intracellular calcium were detected using
the ﬂuorescent probe Fura2-AM [23]. Primary cultured
cardiomyocytes were placed in a buﬀered physiological
saline solution containing 140mmol/L NaCl, 5.9mmol/L
KCl, 1.2mmol/L CaCl2, 1.4mmol/L MgCl2, 11.5mmol/L
glucose, 1.8mmol/L Na2HPO4, and 10mmol/L HEPES-Tris.
A ﬁnal concentration of 5μmol/L Fura-2AM was added to
the cells which were incubated for 1hour in humidiﬁed
5% CO2 and 95% air at 37◦C. The cells were washed and
incubated for an additional 30minutes in PSS. The neonatal
rat cardiomyocytes were inserted into a thermostatic (37◦C)
cuvette containing 2mL of calcium-free PSS and various
doses of dobutamine or inhibitor as previously indicated.
The ﬂuorescence was continuously recorded using a ﬂuo-
rescence spectroﬂuorometer (Hitachi F-2000, Tokyo, Japan).
T h ev a l u e so f[ C a 2+]i were calculated from the ratio R =
F340/F380 by the formula: [Ca2+]i = KdB (R − Rmin)/(Rmax−
R), where Kd is 225nM, F is the ﬂuorescence, and B is
the ratio of the ﬂuorescence of the free dye to that of the
Ca2+-bound dye measured at 380nm. Rmax and Rmin were
determined in separate experiments by using Dobutamine
to equilibrate [Ca2+]i with ambient [Ca2+]( Rmax), and the
addition of 0.1mmol/L MnCl2 and 1mmol/L EGTA (Rmin).
Background autoﬂuorescence was measured in unloaded
cells and subtracted from all experimental measurements.
2.6.SmallInterferingRNA(siRNA). DuplexedRNAoligonu-
cleotides for rat PPARδ (Stealth RNAi) were synthesized by
Invitrogen using our previous method [24]. The neonatal
rat cardiomyocytes were transfected with 40pmol of PPARδ-
speciﬁc siRNA (siRNA-PPARδ) or scramble siRNA using
Lipofectamine 2000 (Invitrogen) according to the manu-
facturer’s protocols. These cardiomyocytes were subjected
to experimental conditions as described above for 48hours
posttransfection. The sequences of the siRNA-PPARδ are
UUGCAGAUCCGAUCGCACUUCUCGU (sense strand)
and ACGAGAAGUGCGAUCGGAUCUGCAA (antisense
strand) as described previously [24].
2.7. Statistical Analysis. Statistical analysis was carried out
using an ANOVA and the Newman-Keuls post-hoc analysis.
Statistical signiﬁcance was set as P<0.05. The results were
expressed as mean ± SEM.
3. Results
3.1. Increase of PPARδ Expression by Dobutamine in Neona-
tal Rat Cardiomyocytes. The neonatal rat cardiomyocytes
were treated with dobutamine to identify the changes
in PPARδ expression. Treatment with dobutamine at
0.1μmol/L increased PPARδ protein expression level in a
time-dependent manner (Figure 1(b)) and the levels in these
cells were increased to maximum at 4hours later of drug
treatment.Dobutaminewasthenincubatedfor4hatvarious
concentrations ranging from 0.01 to 10μmol/L. The PPARδ
protein expression levels in neonatal rat cardiomyocytes
were increased by dobutamine in a concentration-dependent
manner (Figure 1(a)).4 The Scientiﬁc World Journal
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Figure 2: Eﬀects of receptor antagonists, protein kinase A inhibitor, and calcium chelater on dobutamine-induced actions in neonatal rat
cardiomyocytes. The neonatal rat cardiomyocytes were treated with atenolol, butoxamine, PKAI or BAPTA-AM at indicated concentration
for 30minutes prior to incubation with 1μmol/L dobutamine. All drugs were dissolved in normal medium. Cells treated with the same
volume of normal medium only are indicated as the vehicle-treated control. The treated cells were then harvested to measure PPARδ protein
expression (a, c, d) and cTnI phosphorylation (b, e) using Western blotting analysis. All values are expressed as mean ± SEM (n = 6p e r
group). ∗P<0.05 as compared with the vehicle-treated control. #P<0.05 as compared to cells treated with dobutamine only.The Scientiﬁc World Journal 5
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Figure 3: Eﬀects of calcium-mediated signaling inhibitors on dobutamine-induced actions in neonatal rat cardiomyocytes. The neonatal rat
cardiomyocytes were treated with 1μmol/L cyclosporine A (CsA, calcineurin inhibitor) or 1μmol/L KN93 (CaMK inhibitor) at 30minutes
prior to incubation with 1μmol/L dobutamine for 4 hours. The cells were then harvested to measure PPARδ protein expression (a) and cTnI
phosphorylation (b) using Western blotting analysis. All values are expressed as mean ± SEM (n = 6 per group). ∗∗P<0.01 as compared
with control cells. ##P<0.01 as compared to the control cells incubated with dobutamine only.
3.2. Eﬀects of Atenolol and Butoxamine on Dobutamine-In-
duced Actions in Neonatal Rat Cardiomyocytes. To determine
the receptor involved in dobutamine-induced the expres-
sions of PPARδ and the phosphorylation of cTnI, we treated
the cells with atenolol at a concentration suﬃcient to block
the β1-adrenoceptor [19, 20] and butoxamine to block the
β2-adrenoceptor [21]. The increases in PPARδ expression
andcTnIphosphorylationduetodobutaminewereinhibited
by 10μmol/L of atenolol (Figures 2(a) and 2(b)); however,
butoxamine failed to modify the actions of dobutamine
(Figures 2(a) and 2(b)).
3.3. Eﬀect of Protein Kinase A Inhibitor on Dobutamine-
Induced Actions in Neonatal Rat Cardiomyocytes. The β1-
adrenoceptor is known to couple to adenylyl cyclase [2–6].
An increase of cyclic AMP causes protein kinase A (PKA)
activation which results in higher levels of PPARδ protein
expression [25, 26]. Thus, we used the speciﬁc inhibitor of
protein kinase A (PKAI) to verify the roles of PKA in changes
of PPARδ expressions. The dobutamine-induced increases of
PPARδ expressionwerereducedbytreatmentwith10μmol/L
of PKAI (Figure 2(c)).
3.4. Eﬀects of Intracellular Calcium Levels on Dobutamine-
Induced Actions in Neonatal Rat Cardiomyocytes. The ﬂuo-
rescent probe, Fura2-AM is used to detect the intracellu-
lar calcium concentration in neonatal rat cardiomyocytes.
Dobutamine increased the intracellular calcium levels from
155.4+1 1 .4nmol/L to 484.7+2 2 .4nmol/L (n = 8)
at 0.1μmol/L and increased in a concentration-dependent
manner. Pretreatment of the cells with the calcium chela-
tor BAPTA-AM (BAPTA) at an eﬀective concentration
(25μmol/L) [27] reduced the actions of dobutamine on the
increases of PPARδ expression and cTnI phosphorylation
(Figures 2(d) and 2(e)).
3.5. Calcium-Related Pathway as the Possible Signal for
Dobutamine-Induced Actions in Neonatal Rat Cardiomy-
ocytes. Cyclosporine A (CsA, a calcineurin inhibitor) and
KN93 (a calcium/calmodulin kinase inhibitor) were used
to investigate whether dobutamine-induced PPARδ expres-
sion is mediated through the activation of calcium-related
pathway [22]. The dobutamine-induced increases in PPARδ
expression and cTnI phosphorylation were markedly inhib-
ited by either 1μmol/L of CsA or 1μmol/L of KN93
(Figures 3(a) and 3(b)).
3.6. Eﬀects of siRNA-PPARδ on Dobutamine-Induced Actions
in Neonatal Rat Cardiomyocytes. The neonatal rat cardio-
myocytes were transfected with either siRNA targeted to
PPARδ or a scramble control for 48hours, as described
previously [24]. After treatment with dobutamine, PPARδ
expression was markedly reduced in the cardiomyocytes
that were transfected with the siRNA targeted to PPARδ
(Figure 4(a)). The cells transfected the siRNA-scramble
did not aﬀect dobutamine-induced increase of PPARδ
expression (Figure 4(a)). Moreover, dobutamine-induced
TnI phosphorylation was also reduced in cells treated
with siRNA-PPARδ but remained unchanged in the cells
transfected with siRNA-scramble (Figure 4(b)).6 The Scientiﬁc World Journal
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Figure 4: Eﬀects of PPARδ-targeted siRNA on dobutamine-induced actions in neonatal rat cardiomyocytes. The neonatal rat cardiomyocytes
transfected with siRNA-targeted to PPARδ or siRNA-scramble (siRNA-control) were incubated with 1μmol/L dobutamine. All cells were
then harvested to measure PPARδ expression (a) or cTnI phosphorylation (b) using Western blotting analysis. All values are expressed as
mean ± SEM (n = 6 per group). ∗P<0.05 as compared with the vehicle-treated control and #P<0.05 as compared with the dobutamine-
treated cells transfected with the scramble siRNA (siRNA-control).
4. Discussion
In the present study, treatment with dobutamine in neona-
tal rat cardiomyocytes caused a concentration-dependent
increase in both PPARδ protein expression and cTnI phos-
phorylation. These increases induced by dobutamine were
blocked by pretreatment with atenolol, PKAI, KN93, CsA,
or BAPTA. Moreover, the dobutamine-induced increases
in PPARδ protein expression and cTnI phosphorylation
were markedly reduced in neonatal rat cardiomyocytes that
were transfected with siRNA targeted to PPARδ.T h u s ,
the mediation of PPARδ in dobutamine-induced cardiac
action can be considered. It has been reported that PPARδ
is involved in excitation-transcription coupling [28]a n d
that calcineurin-mediated skeletal muscle reprogramming
induces the expression of several transcriptional regulators,
including PPARδ [29]. Taken together, we suggest that the
increase in PPARδ expression by dobutamine is mainly
induced by an activation of the β1-adrenoceptor, which
resultsinanincreaseofintracellularcAMPandcalcium.This
leads to an increase in heart contractility.
Regulation of PPARδ expression in cardiac muscles
through the intracellular Ca2+ signaling pathway has been
established [22, 30, 31]. We show that treatment with
BAPTA suppressed dobutamine-induced PPARδ protein
expression. We also show that the inhibition of PKA reduced
dobutamine-induced expression of PPARδ. This result is
consistentwiththeﬁndingthattheactivationofPKAinduces
intracellular calcium release [32]. Thus, dobutamine exerts
its eﬀects on PPARδ expression in a calcium-dependent
manner via the activation of PKA in cardiac cells.
It has been demonstrated that cTnI phosphorylation
most likely occurs due to an enhanced oﬀ rate during Ca2+
exchange with the cardiac troponin calcium binding site,
leading to an acceleration of relaxation and an increase in
cardiac output [31, 33–36]. Similarly, we found that cTnI
phosphorylation is elevated in neonatal rat cardiomyocytes
after treatment with dobutamine. We also observed that
pretreatment with calcium chelater (BAPTA) decreased
the levels of cTnI phosphorylation in dobutamine-treated
cardiomyocytes. Therefore, we suggest that the increase
in intracellular calcium is responsible for the increase of
cTnI phosphorylation by dobutamine. This explanation is
consistent with previously published reports [31, 33–36].
T h er o l eo fP P A R δ in the phosphorylation of cTnI in
cardiomyocytes remains unclear. Thus, we applied PPARδ-
targeted siRNA to better characterize this possible rela-
tionship. In this study, a 48 hours transfection of siRNA-
PPARδ in cardiomyocytes suppressed dobutamine-induced
cTnI phosphorylation. Thus, it is suggested that PPARδ is
involved in dobutamine-induced cTnI phosphorylation in
cardiomyocytes.
In conclusion, we demonstrated that treatment with
dobutamine in neonatal rat cardiomyocytes can increase
PPARδ expression by an activation of the β1-adrenoceptor
through cAMP to activate PKA and increase intracellular
calcium levels. This increase may induce calmodulin and
calcineurin activation which could result in higher PPARδ
protein expression. Taken together, increases in PPARδ
proteinexpressionandcTnIphosphorylationareresponsible
for dobutamine-induced cardiac action, suggesting a new
mechanism for dobutamine-induced cardiac contraction.The Scientiﬁc World Journal 7
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